Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. develops genome editing medicines using CRISPR systems for serious diseases. Company news centers on its in vivo pipeline, including EDIT-401, an LDLR-targeted development candidate designed to treat hyperlipidemia by increasing LDLR protein expression and reducing LDL cholesterol.
Recurring updates include quarterly financial results, business highlights, scientific conference presentations, preclinical data for EDIT-401, intellectual property developments involving CRISPR/Cas9 patent interference, and investor conference participation. The company also reports on pipeline prioritization and its licensed Cas12a and Cas9 patent estates for human medicines.
Editas Medicine, a clinical stage genome editing company, will have its President and CEO, Gilmore O’Neill, present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA. The presentation will be accessible via live webcast on the company’s website, with an archived replay available for 30 days post-event. Editas Medicine focuses on developing transformative genomic medicines using CRISPR technology to treat serious diseases globally, holding exclusive licenses for key patents.
Editas Medicine announced positive initial clinical data from the first two patients treated with EDIT-301 for severe sickle cell disease (SCD) in the Phase 1/2 RUBY trial. Both patients demonstrated successful engraftment without vaso-occlusive events during follow-up. The first patient achieved a total hemoglobin level of 16.4 g/dL and 45.4% fetal hemoglobin five months after treatment. EDIT-301 showed a favorable safety profile, consistent with myeloablative conditioning. The company plans to present further updates in mid-2023.
Editas Medicine (Nasdaq: EDIT) will host a webinar on December 6 at 8:00 a.m. ET to present initial clinical data from the Phase 1/2 RUBY trial of EDIT-301, aimed at treating severe sickle cell disease. The data will cover safety results from the first two patients and efficacy findings from the first patient treated. Sickle cell disease affects approximately 100,000 individuals in the U.S., causing severe health issues. EDIT-301 is an experimental therapy designed to enhance fetal hemoglobin production, potentially offering durable treatment benefits.
Editas Medicine (Nasdaq: EDIT) announces promising results from the Phase 1/2 BRILLIANCE trial of EDIT-101, a CRISPR/Cas9 treatment for Leber congenital amaurosis 10 (LCA10). The trial showed a favorable safety profile, with no serious adverse events, and preliminary efficacy signals indicated improvements in best corrected visual acuity (BCVA) for three out of 14 treated patients. However, due to the small patient population, the company will pause enrollment in the trial and seek a collaboration partner for further development.
Editas Medicine, Inc. (Nasdaq: EDIT) announced significant advancements in its clinical trials, including the second patient dosed in the Phase 1/2 RUBY trial for sickle cell disease, with preliminary clinical data expected by year-end 2022. The company also completed cell editing for the first patient in the EDITHAL trial for transfusion-dependent beta thalassemia and will provide a clinical update on the BRILLIANCE trial for EDIT-101 this month. Financially, Editas reported a net loss of $55.7 million for Q3 2022, up from $39.1 million in Q3 2021, with cash reserves of $478.5 million.
Editas Medicine, a clinical-stage genome editing company, will host a conference call on November 2, 2022, at 8:00 a.m. ET to discuss its third-quarter results. U.S. callers can dial 877-407-0989, while international participants can call 201-389-0921. The call will also be available via webcast on the company's website, with a replay accessible after the call. Editas Medicine specializes in developing transformative genomic medicines utilizing CRISPR technology.
Editas Medicine reported promising preclinical results for its experimental medicine EDIT-103, aimed at treating rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP). The study, presented at the European Society of Gene and Cell Therapy meeting, showcased nearly 100% gene editing in non-human primates with more than 30% of replacement protein levels achieved. This CRISPR/Cas9-based therapy demonstrated effective knockout and replacement of the defective RHO gene with indications of preserved photoreceptor function, advancing towards IND-enabling studies.
Editas Medicine (Nasdaq: EDIT), a leader in genome editing, announced its participation in several upcoming investor conferences. The events include the 2022 Wells Fargo Healthcare Conference on September 7, with a 1:55 p.m. ET fireside chat in Everett, MA; the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, at 10:30 a.m. ET in New York, NY; and the Baird 2022 Global Healthcare Conference on September 13 in New York, NY. The chats will be webcast live and archived for 30 days on the company’s website.
Editas Medicine announced key developments, including the successful engraftment of the first patient treated with EDIT-301 for sickle cell disease and the removal of the FDA's partial clinical hold on the RUBY trial. The company appointed Baisong Mei, M.D., Ph.D., as Chief Medical Officer to strengthen its leadership team. Financially, Editas reported a net loss of $53.5 million for Q2 2022, with cash reserves of $527.6 million, sufficient to fund operations through 2024. EDIT-301 received FDA Orphan Drug Designation for transfusion-dependent beta thalassemia, and collaborations for cancer therapies were announced with Immatics and Bristol Myers Squibb.
Editas Medicine has successfully dosed and achieved neutrophil and platelet engraftment in the first patient in the Phase 1/2 RUBY trial of EDIT-301 for severe sickle cell disease. This marks the first clinical application of the AsCas12a enzyme for human gene editing. The FDA has lifted a partial hold on the trial, allowing the inclusion of efficacy data for future marketing applications. Additional patients are being enrolled across multiple U.S. and Canadian sites, with top-line clinical results expected by year-end 2022.